-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In Europe, breast cancer is the most common cancer among women, the most common cause of death among Hispanic women, and the second most common cause of death among women of other races (after lung cancer).
Breast cancer
The National Institute of Health and Care Excellence (NICE) recommends Novartis's Kisqali routinely in some patients with advanced breast cancer.
Since 2019, Kisqali been through cancer drug fund provided to patients will (CDF), while collecting more evidence to resolve the uncertainty about how much overall survival and cost-effectiveness of the drug may be extended.
The fund NICE said in a statement that new evidence shows that fulvestrant combined with Kisqali treatment can significantly extend the life of breast cancer patients compared to fulvestrant alone.
Original source:
Original source:http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http:// Leave a message here